IDEXX Laboratories, Inc. vs Uranium Energy Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: IDEXX Laboratories, Inc. is far larger — about 8.9× Uranium Energy Corp's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 10,888,578). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Uranium Energy Corp for 37 Days on average.
| IDXX | UEC | |
|---|---|---|
Market Cap | $40.43B | $4.53B |
Volume | 692,164 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $766.68 | $20.14 |
52-Week Low | $504.70 | $9.04 |
Typical Hold Time | 46 Days | 37 Days |
Enterprise Value | $41.32B | $4.03B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Uranium Energy (UEC) trades at $9.14, down 3.48% in the last session, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37 million but posted a net loss of $137 million, reflecting ongoing operational challenges. Recent news highlights UEC's expansion to two operating mines and strong uranium pricing at $93.13 per pound, though production sustainability remains unproven. Technical indicators show bearish momentum with resistance at $10 and support at $9.
UEC presents a high-risk opportunity with significant analyst optimism (87.5% buy ratings) and a consensus price target of $16.06, offering 75% upside potential. However, persistent negative earnings, cash flow challenges, and dependence on uranium market dynamics pose substantial risks. Investors should weigh the company's strategic positioning in domestic uranium production against its current financial performance and execution risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →